Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. (ERAS) has a notice that Erasca Foundation intends to sell common stock under Rule 144. The Foundation plans to sell 8,333 shares$133,093.91
The filing also lists prior sales by Erasca Foundation over the past three months and discloses that the Foundation originally acquired 10,193,557 shares
Erasca, Inc. (ERAS) reports that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to its product candidate ERAS-0015 for treating patients with metastatic pancreatic adenocarcinoma. FTD is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs through more frequent FDA interactions and potential access to accelerated approval, priority review, and rolling review if relevant criteria are met.
Erasca notes that FTD does not change approval standards and may not shorten review time or increase the likelihood of marketing approval. The company highlights plans involving ERAS-0015, including a potential phase 3 trial in pancreatic cancer and two potentially registration-enabling trials in lung cancer, while emphasizing significant clinical, regulatory, and safety risks and uncertainties.
Erasca Foundation filed a notice of proposed sale of Erasca, Inc. common stock under Form 144. The filing lists a planned sale of 8,333 common shares of Erasca, Inc. through Merrill Lynch on NASDAQ with an aggregate value of $152,418.71.
The notice also references a prior donation of 10,193,557 common shares of Erasca, Inc. dated July 20, 2021, and reports sales during the past three months by Erasca Foundation of 8,333 shares for $157,637.52 on July 21, 2026 and 8,333 shares for $117,476.95 on June 15, 2026.
Erasca, Inc. has updated institutional and insider ownership information for its common stock. As of June 30, 2026, based on 349,762,035 shares outstanding as of August 4, 2026, City Hill, LLC beneficially owns 12,899,360 shares, all with shared voting and dispositive power. Jonathan E. Lim may be deemed to beneficially own 36,968,486 shares, or 10.4% of the common stock, including 4,612,910 shares underlying stock options exercisable within 60 days and shares held by City Hill, LLC and a family trust. Conyee T. Lim may be deemed to beneficially own 19,456,216 shares, or 5.6%, through shared voting and dispositive power as co-trustee of the same family trust.
Erasca, Inc. reported that President, R&D Charles S. Fuchs received a grant of stock options covering 1,300,000 shares of common stock with an exercise price of $18.12 per share. The award was granted in connection with his commencement of employment and vests 25% after one year, with the remaining 75% vesting in 36 monthly installments, subject to continued service. Following this grant, he holds options for 1,300,000 shares.
Erasca, Inc. officer Charles S. Fuchs, serving as President, R&D, submitted an initial statement of beneficial ownership of securities as a reporting person. The filing lists no reportable transactions or derivative positions and shows no buy, sell, acquisition, or disposition activity.
Erasca, Inc. reported a larger net loss while significantly strengthening its balance sheet and advancing its RAS/MAPK oncology pipeline for the quarter ended June 30, 2026. Net loss was $44.1 million for the quarter and $227.5 million for the first six months of 2026, compared with $33.9 million and $64.8 million in the prior-year periods, driven largely by a $150.0 million in‑process R&D charge to expand territorial rights under the Joyo pan‑RAS license.
Total assets were $435.1 million, including $384.3 million in cash, cash equivalents, and marketable securities. A January 2026 underwritten offering provided $242.7 million in net proceeds, and a subsequent July 2026 offering added $593.5 million, which management believes will fund operations for at least one year from issuance of these statements.
The company is focusing on ERAS-0015, a pan‑RAS molecular glue, and ERAS-4001, a pan‑KRAS inhibitor. Preliminary Phase 1 data for ERAS‑0015 showed encouraging response rates in KRAS G12X non‑small‑cell lung cancer and pancreatic adenocarcinoma with a generally manageable safety profile, while development of naporafenib under the Novartis agreement has been discontinued.
Erasca, Inc. reported second quarter 2026 results and business updates centered on its RAS/MAPK-targeted oncology pipeline. Lead candidate ERAS-0015 showed a 57% uORR8wk as monotherapy in second-line or later KRAS G12X pancreatic cancer at the 32 mg once-daily dose, with ongoing treatment for all responders and favorable tolerability, including no dose-limiting toxicities or treatment-related discontinuations. The company is advancing ERAS-0015 toward three potentially registration-enabling trials in pancreatic and lung cancers, with multiple Phase 1 monotherapy and combination data readouts expected in the first half of 2027. ERAS-4001, a potential first-in-class pan-KRAS inhibitor, has preliminary Phase 1 monotherapy data expected in the second half of 2026.
Cash, cash equivalents, and marketable securities were $384.3 million as of June 30, 2026, up from $341.8 million at year-end 2025, and were further bolstered by an upsized July 2026 public offering raising approximately $632.5 million in gross proceeds. The company expects its capital, including proceeds from the July offering, to be sufficient to fund its stated key upcoming milestones. For the quarter, research and development expenses were $35.9 million, general and administrative expenses were $11.7 million, and net loss was $44.1 million, or $(0.14) per share, compared with a net loss of $33.9 million, or $(0.12) per share, in the prior-year quarter.
Erasca, Inc. appointed Charles S. Fuchs, M.D., M.P.H., age 66, as President, Research & Development effective August 10, 2026. He has more than three decades of oncology leadership across academia and biopharmaceutical companies, including senior roles at Genentech, Roche, Tubulis, Yale Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute. There are no related-party relationships or appointment arrangements disclosed.
Under an employment offer letter, Dr. Fuchs will receive an annual base salary of $570,000, a target bonus equal to 45% of base salary, and stock options to purchase 1,300,000 shares of common stock, vesting over four years. Of these, 1,278,520 options were granted under a newly adopted 2026 Employment Inducement Incentive Award Plan, with 6,200,000 shares reserved for awards. The options will have an exercise price equal to the closing price on the grant date. Dr. Fuchs is designated a Tier 1 Covered Employee under the company’s severance plan and has entered into the company’s standard indemnification agreement.
Erasca Foundation has filed to sell common stock of Erasca, Inc. under a Form 144 notice. The planned sale covers 8,333 shares of common stock through Merrill Lynch, with an aggregate market value of $157,637.52, and is expected on July 21, 2026 on NASDAQ. The Foundation previously received 10,193,557 shares as a donation from Erasca, Inc. on July 20, 2021 and has already sold 8,333 shares on May 15, 2026 for $84,528.29 and another 8,333 shares on June 15, 2026 for $117,476.95.